12,891 research outputs found
Reading by Jo Walton
No full textAward-winning author and Mythopoeic Fantasy Award finalist Jo Walton will read from her works and answer questions from the audience
Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan
No full textRadioimmunotherapies with Zevalin® (RIT-Z) showed encouraging results in patients with relapsed/refractory follicular lymphoma (FL), leading frequently to failure-free intervals longer than those achieved by the last previous therapy. We compared time-to-event variables obtained before and after RIT-Z in patients with relapsed FL, previously exposed to rituximab. All patients with relapsed non-transformed, non-refractory, non-rituximab-naïve FL who have been treated with RIT-Z in two different centres in Europe were included. Staging and response were assessed by contrast-enhanced CT in all patients; PET/CT was performed according to local availability. Event-free survival (EFS) and time to next treatment (TTNT) following the last previous therapy and after RIT-Z were compared. Pre-therapy characteristics were tested in univariate analyses for prediction of outcomes. A description of the patterns of relapse was also provided. Among 70 patients treated, only 16 fulfilled the inclusion criteria. They were treated with a median of 3 prior lines of chemo-immunotherapies, including a median of 2 rituximab-containing regimens; 6 patients had undergone myeloablative chemotherapy with autologous stem cell rescue (ASCT). Overall response rates were 10 (62%) CR/CRu, 3 (19%) PR and 3 (19%) PD; response rates were similar in patients with prior ASCT. After RIT-Z only few patients obtained EFS and TTNT longer than after the last previous therapy. All four patients receiving rituximab maintenance were without progression 12 months after RIT-Z. Relapses occurred in both previously and newly involved sites; a significant association was found between the number of pathologic sites involved prior to RIT-Z and subsequent TTNT. Despite the excellent response rate, the duration of response was shorter than the previous one confirming the known trend of relapses to occur earlier after subsequent treatments. Rituximab maintenance after RIT-Z showed encouraging results in terms of prolonging EFS, warranting further studies.Radioimmunotherapies with Zevalin® (RIT-Z) showed encouraging results in patients with relapsed/refractory follicular lymphoma (FL), leading frequently to failure-free intervals longer than those achieved by the last previous therapy. We compared time-to-event variables obtained before and after RIT-Z in patients with relapsed FL, previously exposed to rituximab. All patients with relapsed non-transformed, non-refractory, non-rituximab-naïve FL who have been treated with RIT-Z in two different centres in Europe were included. Staging and response were assessed by contrast-enhanced CT in all patients; PET/CT was performed according to local availability. Event-free survival (EFS) and time to next treatment (TTNT) following the last previous therapy and after RIT-Z were compared. Pre-therapy characteristics were tested in univariate analyses for prediction of outcomes. A description of the patterns of relapse was also provided. Among 70 patients treated, only 16 fulfilled the inclusion criteria. They were treated with a median of 3 prior lines of chemo-immunotherapies, including a median of 2 rituximab-containing regimens; 6 patients had undergone myeloablative chemotherapy with autologous stem cell rescue (ASCT). Overall response rates were 10 (62%) CR/CRu, 3 (19%) PR and 3 (19%) PD; response rates were similar in patients with prior ASCT. After RIT-Z only few patients obtained EFS and TTNT longer than after the last previous therapy. All four patients receiving rituximab maintenance were without progression 12 months after RIT-Z. Relapses occurred in both previously and newly involved sites; a significant association was found between the number of pathologic sites involved prior to RIT-Z and subsequent TTNT. Despite the excellent response rate, the duration of response was shorter than the previous one confirming the known trend of relapses to occur earlier after subsequent treatments. Rituximab maintenance after RIT-Z showed encouraging results in terms of prolonging EFS, warranting further studies
Recognition of prior learning: at a glance
No full textRecognition of prior learning is a process whereby people have the skills and knowledge they have developed outside the formal education system assessed and valued against qualifications frameworks. Jo Hargreaves gives an overview of recent research into recognition of prior learning within the Australian vocational education and training system
Bonnie Jo Campbell, 33rd Annual ODU Literary Festival
No full textBonnie Jo Campbell is the author of Women and Other Animals, Q Road, and American Salvage. She is the winner of the AWP Award for Short Fiction and the Southern Review’s 2008 Eudora Welty Prize. Her stories have appeared in Southern Review, Kenyon Review, and Ontario Review. American Salvage was a 2009 finalist for the National Book Award in Fiction
Autograph of Jo Mink Dunham in "From Self-Esteem to Sex-Esteem"
No full textThe title page and an autograph by the author, Jo Mink Dunham, in their work ""From Self-Esteem to Sex-Esteem: Lessons from the Gender Evolution of 'The Girls'"" with an inscription.To Gloria - August 26, 2015 I hope we meet some day. I would love to work with you in some way. This book did not have a wide distribution and the timing of a new release or enhanced edition would be, I believe, well received now should you be interested. jo dunha
Should we include SPECT lung perfusion in radiotherapy treatment plans of thoracic targets? Evidences from the literature.
No full textTo report the available data about the potential impact of integrating lung perfusion SPECT/CT in treatment plans optimization for the irradiation of thoracic targets.
MATERIALS AND METHODS:
We searched in the PubMed and Scopus databases, English-written articles published from 2000 to June 2015 dealing with the integration of perfusion SPECT/CT in radiotherapy.
RESULTS:
We found and analyzed 16 research articles (10 dosimetric, 6 clinical) for a total of 578 patients. Available data suggest dosimetric and clinical improvements when perfusion SPEC/CT is integrated in the radiotherapy treatment planing of selected patients with thoracic targets. In particular, patients presenting emphysema and/or large areas of deficit of perfusion show the most important improvements. Moreover, some studies show different risk of radiation pneumonitis (RP) depending on the localization of the tumor in the lungs: patients with low-located tumors, present an increased risk of RP, and functional data could be a benefit in treatment plan optimization. Unfortunately, none of the available studies finally reports any dosimetric constraint, which could be used in the clinical practice, even if most of them used the cut-off of the 30% of the maximal perfusion value to define the well-functioning lung.
CONCLUSIONS:
Published data support the integration of lung perfusion scintigraphy in some selected categories of patients. Prospective studies should be designed to define the best candidates, and to assess the clinical advantage of this kind of optimization
Séquence 11, L'accusation, raconté par Jo
No full textCette séquence fait partie du corpus vidéo de Langue des Signes Emergentes utilisé lors de la thèse d'Ivani Fusellier-Souza : le locuteur Jo raconte qu'il n'aime pas une personne que Manoël connaît et avec qui il discute.00:00:00>00:00:03 Manoël incite Jo à raconter à l'interlocuteur une histoire. 00:00:03>00:00:05 Jo dit que Manoël raconte n'importe quoi. 00:00:06>00:00:09 Manoël insiste pour que Jo parle. 00:00:10>00:00:13 Jo refuse. 00:00:13>00:00:16 Manoël insiste une nouvelle fois. Rire entre les deux hommes. 00:00:16>00:00:18 Jo dit qu'ils boivent tous les deux. 00:00:18>00:00:19 Manoël l'interpelle et lui dit que c'est uniquement lui. 00:00:19>00:00:20 Jo insiste sur le fait que ce soit eux deux. 00:00:20>00:00:21 Manoël dit que lui, il n'a rien à voir. 00:00:21>00:00:29 Jo répète que lui et Manoël boivent en jouant au billard. 00:00:30>00:00:31 Manoël parle d'un ami aux cheveux longs. 00:00:31>00:00:35 Jo répète ce qu'a dit Manoël. Et parle à son tour d'une personne aux lèvres arrondies. 00:00:35>00:00:37 Manoël nie. 00:00:37>00:00:59 Jo raconte que cette personne aux lèvres arrondies, il ne l'aime pas et a envie de lui « casser la figure » alors que Manoël aime bien discuter avec elle
Séquence 15, L'accident, raconté par Jo
No full textCette séquence fait partie du corpus vidéo de Langue des Signes Emergentes utilisé lors de la thèse d'Ivani Fusellier-Souza : le locuteur Jo raconte un accident dont il a été témoin entre un cycliste et une voiture à un croisement.00:00:00>00:00:02 Manoël demande à Jo de parler du vélo à l'interlocuteur. 00:00:02>00:00:11 Jo raconte qu'il y a eu un accident de vélo. 00:00:11>00:00:12 Manoël demande si Jo l'a vu de ses propres yeux. 00:00:12>00:00:36 Jo dit que oui. Il raconte qu'à un croisement, une voiture a eu un accident avec un cycliste. Le conducteur de la voiture a eu une amende. 00:00:36>00:00:40 Manoël lui demande s'il s'agit bien du vélo. 00:00:40>00:00:54 Jo raconte que l'accident s'est passé sur une route juste devant. 00:00:54>00:00:56 Manoël demande si le cycliste est mort. 00:00:56>00:00:59 Jo répond qu'il n'est pas mort et qu'il est parti. 00:00:59>00:01:00 Manoël explique à l'interlocuteur le signe pour « mort ». 00:01:00>00:01:21 Jo raconte que le cycliste a été blessé et qu'une voiture a été appelée pour le ramener
Séquence 10, L'oncle Amauri, raconté par Jo
No full textCette séquence fait partie du corpus vidéo de Langue des Signes Emergentes utilisé lors de la thèse d'Ivani Fusellier-Souza : le locuteur Jo raconte avec Manoël qui est son oncle Amauri, un homme grand et fort qui a une hernie.00:00:00>00:00:10 Jo présente son oncle Amauri. 00:00:10>00:00:11 Manoël réexplique qui est l'oncle. 00:00:11>00:00:29 Jo raconte que c'est de son oncle qu'il parle, un homme grand et fort. 00:00:29>00:00:43 Manoël raconte à Jo que sa mère lui a dit que l'oncle n'avait plus son hernie et qu'il ne conduisait plus aussi
Séquence 5, Problèmes au boulot 1, raconté par Jo
No full textCette séquence fait partie du corpus vidéo de Langue des Signes Emergentes utilisé lors de la thèse d'Ivani Fusellier-Souza : le locuteur Jo raconte une bagarre qu'il a eu avec un collègue de travail qui s'occupait des ananas.00:00:00>00:00:37 Jo raconte une bagarre qui s'est déroulée à son travail. 00:00:37>00:00:38 L'enquêtrice lui demande si c'est lui qui s'est bagarré. 00:00:39>00:00:49 Jo raconte qu'il s'est bien bagarré avec quelqu'un. 00:00:49>00:00:54 Manuel demande à Jo si il était avec un chariot. 00:00:54>00:00:55 Jo lui dit que non. 00:00:55>00:00:56 Manuel lui demande alors avec quoi il était. 00:00:57>00:00:57 Jo lui dit que c'était de l'ananas. 00:00:58>00:01:00 Manuel lui redemande s'il était avec un chariot d'ananas. 00:01:00>00:01:01 Jo dit qu'il y en avait beaucoup. 00:01:01>00:01:05 Manuel demande à Jo s'il s'est bien bagarré à son travail. 00:01:05>00:01:08 Jo le lui confirme et dit qu'il s'agissait de celui de l'ananas. 00:01:08>00:01:10 Manuel réexplique, et dit qu'il y avait beaucoup d'ananas. 00:01:10>00:01:31 Jo raconte une nouvelle fois sa bagarre
- …
